Publications by authors named "M Rummel"
The short-term scaling exponent of detrended fluctuation analysis (DFAα1) applied to interbeat intervals may provide a method to identify ventilatory thresholds and indicate systemic perturbation during prolonged exercise. The purposes of this study were to (i) identify the gas exchange threshold (GET) and respiratory compensation point (RCP) using DFAα1 values of 0.75 and 0.
View Article and Find Full Text PDFArticle Synopsis
- Third-generation chimeric antigen receptor T cells (CARTs) may offer better treatment for relapsed or refractory chronic lymphocytic leukemia (CLL) compared to second-generation CARTs due to improved design.
- In a phase 1/2 clinical trial with nine heavily pretreated patients, HD-CAR-1 targeting CD19 resulted in a significant response where 67% of patients achieved complete remission by day 90, with some showing undetectable minimal residual disease.
- The trial noted low toxicity, with only one case of severe cytokine release syndrome, while those who responded to treatment had a higher presence of CD4+ T cells compared to non-responders.
Article Synopsis
- * This pilot study aimed to integrate a remote exam device into a complex care clinic during the COVID-19 pandemic, focusing on training caregivers and evaluating the device's usability and feasibility.
- * While caregivers rated the device as highly usable, providers found it less so, and technology issues led to 15% of telemedicine encounters being canceled or cut short; overall, the device was successfully incorporated into the clinic.
The short-term scaling exponent alpha1 of detrended fluctuation analysis (DFA-a1) of heart rate variability (HRV) has been shown to be a sensitive marker for assessing global organismic demands. The wide dynamic range within the exercise intensity spectrum and the relationship to established physiologic threshold boundaries potentially allow in-field use and also open opportunities to provide real-time feedback. The present study expands the idea of using everyday workout data from the AI Endurance app to obtain the relationship between cycling power and DFA-a1.
View Article and Find Full Text PDFArticle Synopsis
- Mantle cell lymphoma (MCL) is an incurable B-cell lymphoma and pirtobrutinib has shown promising results in patients who have already undergone multiple treatments, but real-world data is limited.
- A study analyzed 10 MCL patients who received pirtobrutinib from a compassionate use program, revealing a 67% best overall response rate after an average of three previous treatments.
- The findings indicated that pirtobrutinib is a safe and effective treatment option for these patients, with positive outcomes and no new safety concerns reported.